EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability

Jacqueline Lawson iD, Lauren Robinson, Greta R Conlon, Rebecca A Shalev, Paige E Cervantes, Yuliya Yoncheva, Glenn S Hirsch, Andrea B Troxel, Daniel Friedman, Orrin Devinsky, Francisco Xavier Castellanos iD

Journal of Child and Adolescent Psychopharmacology · 01.08.2026 · 36 (6) · 350-358

DOI: 10.1177/10445463261452514 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 28.05.2026. Verfasst von Jacqueline Lawson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Cannabidiol, Autism Spectrum Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Vulnerable Brain Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate cannabidiol (CBD) in pediatric patients with autism spectrum disorder (ASD), fluent verbal language and an estimated full-scale IQ of 80 or above.

Background

Preliminary evidence suggests CBD may ameliorate challenges associated with ASD. Whether CBD benefits pediatric ASD without accompanying intellectual or language impairment remains unknown.

Methods

We enrolled 23 participants, ages 7.8–17.8 (Mean [M] = 11.3 ± 2.8) with ASD and IQ ≥ 80 in a 6-week Phase-2 open-label trial of ≥98% CBD (Epidiolex ® , 100 mg/mL) at 3, 6, or 9 mg/kg/day using a Bayesian optimal interval dosing design. The primary endpoint was the CBD dose associated with the highest response rate (i.e., Clinical Global Impression Scale-Improvement [CGI-I] score = 1 or 2) on a target symptom domain designated individually based on informant report, standardized scales, and clinical observation. Secondary endpoints were effect sizes of changes from baseline in measures assessing ASD core and associated symptoms, and global functioning. Adverse events (AEs) were assessed weekly. Plasma CBD levels and clinical labs were obtained at the final visit.

Results

All 23 enrolled participants completed the trial. The highest response (62%) was observed at 9 mg/kg/day ( N = 8). Overall, 10 of 23 patients (44%) were responders. Response varied across domains: Irritability/Tantrums ( N = 5, 60%), Social ( N = 8, 50%), Anxiety ( N = 5, 40%), Restricted, Repetitive Behaviors ( N = 4, 25%), and Sleep Problems ( N = 1, 0%). Dose correlated with individualized CGI-I (r = −0.42, N = 23, p = 0.04). Individualized domain CGI–Severity scores improved from pre-(M = 4.6 ± 0.5) to post-(M = 3.9 ± 0.8) treatment, t (22) = −4.36, p ≤ 0.001; d = 0.91; 95%CI [0.37,1.03]. Social Responsiveness Scale-2 Total-Score (SRS2-T) had the largest effect size ( p ≤ 0.001; d = 1.36, 95% CI [0.78–1.93]). Of 222 reported AEs, 27 unique AEs were considered treatment-related. Most AEs (93%) were mild and expected (82%); none was severe. The most frequent related AEs were increased salivation (30%), increased sleep duration (39%), sleepiness/sedation (26%), increased dream activity (35%), and polyuria (22%). Vital signs, physical exams, weight, liver function tests, and complete blood counts were unaffected. CBD plasma levels did not correlate with response.

Conclusions

In this preliminary study, CBD was well tolerated; AEs were mild–moderate. Mean SRS2-T and subscores decreased significantly with large effect sizes, shifting from the severe to the moderate range. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT03900923.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolAutism Spectrum DisorderHumansChildMaleFemaleAdolescentDose-Response Relationship, DrugTreatment Outcome

Stichwörter der Autor:innen

ASDCBDadolescentautismautism spectrum disordercannabidiolchildclinical trial

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, New York, USA.

ORCID-Profile: Jacqueline Lawson, Francisco Xavier Castellanos

Förderung

  • Vulnerable Brain Project

Zitieren

APA

Lawson, J., Robinson, L., Conlon, G. R., Shalev, R. A., Cervantes, P. E., Yoncheva, Y., Hirsch, G. S., Troxel, A. B., Friedman, D., Devinsky, O., & Castellanos, F. X. (2026). A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. Journal of Child and Adolescent Psychopharmacology, 36(6), 350-358. https://doi.org/10.1177/10445463261452514

Vancouver

Lawson J, Robinson L, Conlon GR, Shalev RA, Cervantes PE, Yoncheva Y, et al. A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. Journal of Child and Adolescent Psychopharmacology. 2026;36(6):350-358. doi:10.1177/10445463261452514

BibTeX
@article{Lawson2026,
  author = {Lawson, Jacqueline and Robinson, Lauren and Conlon, Greta R and Shalev, Rebecca A and Cervantes, Paige E and Yoncheva, Yuliya and Hirsch, Glenn S and Troxel, Andrea B and Friedman, Daniel and Devinsky, Orrin and Castellanos, Francisco Xavier},
  title = {A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {350--358},
  doi = {10.1177/10445463261452514}
}
Kostenlos starten →